News - Starpharma

Latest News

Starpharma signs new DEP® agreement with MSD

Aug 10th, 2022

Starpharma today announced it has signed a new DEP^® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP^® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP^® dendrimer conjugates and will provide them to MSD for testing and characterisation.

Quarterly Activities Report & Appendix 4C

Jul 29th, 2022

Starpharma today released its Quarterly Activities Report and Appendix 4C for the period ended 30 June 2022.

VIRALEZE Protects Against Omicron in Viral Challenge Model (ASX Announcement)

Jul 20th, 2022

Starpharma today announced new results demonstrating the high level of protection afforded by VIRALEZE™ antiviral nasal spray against the highly infectious SARS-CoV-2 Omicron variant in vivo in a well-established humanised mouse challenge model of coronavirus infection. Challenge models are often used in viral diseases to assess the ability of a product to treat or prevent an infection.

VIRALEZE™ relaunched by LloydsPharmacy in the UK (ASX Announcement)

Jun 30th, 2022

Starpharma today announced that VIRALEZE™ nasal spray has been relaunched by LloydsPharmacy in the UK.

In the media

Australian biotech back on the international stage

Jun 7th, 2022

Starpharma's CEO Dr Jackie Fairley was interviewed by ausbiz during Starpharma's visit to the United States for the American Society of Clinical Oncology (ASCO) Annual Meeting as well as partnering discussions.

Starpharma one of a number of Australian companies in the US for major oncology conference

Jun 7th, 2022

"For the first time in more than two years, a number of Australian biotechnology companies are in the US for one of the world's most important oncology events - the global conference of the American Society of Clinical Oncology (ASCO)." Starpharma featured in Biotech Dispatch during its visit to the United States for ASCO.

Starpharma's nasal spray effective against influenza A & B virus

May 23rd, 2022

BioSpectrum Asia features Viraleze, following Starpharma's announcement about SPL7013's virucidal activity in influenza A and B.

Starpharma’s (ASX:SPL) antiviral agent fights back against against influenza virus

May 18th, 2022

The Market Herald reports on Starpharma’s SPL7013 agent, which achieved up to 99.7 per cent reduction in viral activity against two types of influenzas virus.

Sign up to receive news here